Botulinum Toxins

What Is Botulinum Toxin? A Clinical Introduction
Botulinum toxin is a purified neurotoxic protein that comes from Clostridium botulinum. Injected in small, controlled doses, botulinum toxin type A blocks acetylcholine release at the neuromuscular junction, and the muscle it targets relaxes temporarily as a result. The effect is local and it wears off, which is what makes the protein useful clinically rather than simply dangerous. It is administered by dermatologists, plastic surgeons, neurologists, aesthetic practitioners, and other licensed clinicians across a wide range of cosmetic and therapeutic indications. Botulinum toxin type A carries one of the longest records of clinical evidence among injectables in modern medicine, with the botulinum toxin mechanism of action and therapeutic range documented extensively in the peer-reviewed literature and in regulatory sources. [1]

There are several botulinum toxin serotypes, designated A through G, though clinical practice draws on only two of them. Type A is the standard in aesthetic medicine and in most therapeutic injection protocols. Type B is held in reserve for selected neurological conditions where BTX-A is not indicated. The mechanism of action is consistent across clinical BTX-A formulations: cleavage of SNARE proteins involved in acetylcholine vesicle fusion interrupts nerve signaling to the targeted muscle, and what follows is the temporary functional relaxation the treatment depends on.
Is Botulinum Toxin Destroyed by Heat?
Heat denatures protein-based products, and botulinum toxin is no exception, which is why every BTX-A product carries defined temperature limits. Understanding how botulinum toxin works at the molecular level explains the sensitivity, since the therapeutic effect depends on an intact protein structure reaching the neuromuscular junction. What makes this a practical problem rather than a theoretical one is that a degraded vial gives nothing away. It looks the same, it reconstitutes the same, and the shortfall only shows up in the result. Thresholds differ by product, and the prescribing information governs rather than any general rule.
Is Botulinum Toxin BOTOX®? Understanding the Brand and Generic Distinction
Botulinum toxin is the drug category. BOTOX® is a single branded product within it, manufactured by AbbVie/Allergan. Everyone says “Botox” when they mean any BTX-A injection, patients and practitioners both, and most of the time nothing turns on it. The trouble starts at procurement and dosing, where the shorthand stops being harmless.

These products are not interchangeable. BOTOX® is onabotulinumtoxinA, DYSPORT® is abobotulinumtoxinA, XEOMIN® is incobotulinumtoxinA, and JEUVEAU® is prabotulinumtoxinA. All Botox injections are botulinum toxin, but not all botulinum toxin is BOTOX®. Korean botox brands carry botulinum toxin type A preparations under their own labeling and unit systems, each with its own regulatory standing. Since evidence on glabellar-line treatment shows that BTX-A outcomes are dose-dependent, product-specific labeling is not something to treat as paperwork. [4]
Types of Botulinum Toxin: Serotypes and Clinical Formulations
What matters commercially is not the serotype range but the subdivision within type A. Type B has one product, rimabotulinumtoxinB, marketed as MYOBLOC®, and a correspondingly narrow set of neurological indications, taken up either where BTX-A is not indicated or where antibody formation has eroded the response. Everything else practitioners handle is BTX-A, and the products separate by INN rather than by serotype:

onabotulinumtoxinA: BOTOX®
abobotulinumtoxinA: DYSPORT® and AZZALURE®
incobotulinumtoxinA: XEOMIN® and BOCOUTURE®
prabotulinumtoxinA: JEUVEAU® and NABOTA®

Practitioners occasionally encounter references to botulinum toxin cream. Topical formulations remain an area of ongoing research and do not form part of the current injectable BTX-A category.
Conditions Treated: Aesthetic and Therapeutic Indications
Aesthetic use concentrates in the upper face: glabellar lines, crow’s feet, forehead lines, brow positioning. Lower-face and body indications are less uniform, running from lip flip techniques and masseter reduction for jaw slimming through neck bands and hyperhidrosis, the latter mostly underarm and palmar. Whichever area is being treated, global aesthetic consensus guidance points toward individualized dosing and toward judging outcomes across a full treatment course instead of one session. [2]

Therapeutic indications are where the category shows its range. Practitioners use Botox for migraines, blepharospasm, cervical dystonia, spasticity, and overactive bladder, always within what the specific product is approved for in the specific market. Botulinum toxin in physical therapy and rehabilitation settings tends to mean spasticity management, and there the planning turns on administration technique, target muscle selection, and what the patient actually wants out of treatment. Product choice matters less than any of those.
Dosage, Onset, and Duration
Unit non-interchangeability is one of the most clinically important features of botulinum toxin type A products. Potency units are assay-specific. BOTOX® units, DYSPORT® units, XEOMIN® units, and JEUVEAU® units are not equivalent and cannot be converted between products, and each product’s dosing must follow its own prescribing information.

Onset and duration both sit in ranges rather than at fixed points. Early effects are commonly reported within 3 to 7 days, with full results assessed at around 10 to 14 days post-treatment. Most aesthetic indications then hold for 3 to 4 months, while certain therapeutic applications extend toward 6 months, which depends on the indication, target muscle, dose, and individual response as much as on the product itself.

In patients receiving repeated therapeutic injections over an extended period, the development of neutralizing antibodies has been documented as a factor that may reduce clinical response over time. [3]

Most lyophilized BTX-A products require reconstitution with sterile saline before administration. Reconstitution volume, final concentration, and the permitted window for post-reconstitution use all vary between products and are specified in each product’s IFU. No general figure applies across the category.
Western Botulinum Toxin Brands
Western botulinum toxin brands carry long regulatory histories with the FDA and EMA, and they remain the reference products in the category across most markets.

BOTOX® is the original onabotulinumtoxinA product by AbbVie. It holds extensive FDA approvals across cosmetic and therapeutic indications and functions as the reference point in most BTX clinical and commercial discussions.

DYSPORT® is abobotulinumtoxinA by Ipsen/Galderma, approved for glabellar lines and selected therapeutic indications, with a faster onset reported in clinical practice than some other BTX-A formulations. Units cannot be converted from BOTOX®.

XEOMIN® is incobotulinumtoxinA by Merz. Its formulation contains no complexing proteins, which is why it is described as a “naked” toxin. That property is associated with a room-temperature storage option before reconstitution under specified conditions.

JEUVEAU® is prabotulinumtoxinA by Evolus, FDA-approved for the temporary improvement of moderate-to-severe glabellar lines in adults and positioned primarily as an aesthetic neuromodulator. [5]

BOCOUTURE® is the international aesthetic market name for incobotulinumtoxinA by Merz, the same active substance as XEOMIN®. Similarly, AZZALURE® is the European name for abobotulinumtoxinA by Galderma, the same substance as DYSPORT®, authorized for upper-face dynamic line treatment where approved.
Korean Botulinum Toxin Brands — A Growing Category in Global Aesthetic Practice
South Korea has built a significant position in the global botulinum toxin type A market. Korean botox brands have gained international visibility through competitive pricing, modern pharmaceutical manufacturing standards, a growing clinical evidence base, and well-established export infrastructure.

For practitioners weighing Western against Korean BTX-A products, the decisive considerations are regulatory approval status in the market of use, product documentation, unit calibration, and storage requirements.

NABOTA® is prabotulinumtoxinA by Daewoong. It is the same product marketed in the United States as JEUVEAU® under the Evolus partnership, and it is used widely in Korean and international aesthetic practice.

INNOTOX® is a liquid formulation of botulinum toxin type A by Medytox, supplied pre-diluted and ready to use. Every other product here arrives lyophilized and requires reconstitution, so removing that step is a workflow difference rather than a clinical-efficacy claim. However, for high-volume clinics it shows up in the schedule.

BOTULAX® by Hugel is distributed widely across international markets and is commonly evaluated as a cost-competitive alternative to established Western brands. MEDITOXIN® by Medytox is established in Asian aesthetic markets and exported subject to country-specific requirements. LIZTOX® by Huons is CE-marked and gaining traction in European aesthetic markets. Re N Tox™ is a botulinum toxin type A product by Pharma Research Bio, requiring standard refrigerated storage at 2°C to 8°C and positioned for aesthetic use in markets where it is authorized.
Clinical Benefits of Botulinum Toxin Injections
Botulinum toxin treatment produces predictable, temporary muscle relaxation, provided the right product is selected, dosed, and administered properly. In aesthetic medicine that covers dynamic wrinkles, facial balancing, neck band reduction, and masseter contouring, with very little downtime attached to any of it.

The reversibility is easy to undersell. A new patient is not committing to anything permanent, and whatever the first result looks like can be adjusted at the next appointment rather than lived with. For an injector working with a patient over years, the same property allows dose to be walked up or down as the face changes. Published procedural statistics from bodies including the American Society of Plastic Surgeons put botulinum toxin injections among the most frequently performed minimally invasive procedures anywhere in aesthetics.

Therapeutically, botulinum toxin products have real evidence behind them for migraine, hyperhidrosis, spasticity, dystonia, and blepharospasm. Consensus guidance is clear that outcomes rest on anatomy, administration technique, dose selection, and how often treatment is repeated. [2]
Storage and Shipping Requirements
Most lyophilized botulinum toxin products require refrigerated storage at 2°C to 8°C before use. XEOMIN® and BOCOUTURE® are notable exceptions, since the absence of complexing proteins in incobotulinumtoxinA formulations allows room-temperature storage up to 25°C under specified conditions.

INNOTOX®, as a pre-diluted liquid formulation, requires refrigerated storage and must not be frozen. Other products, Re N Tox™ among them, require standard refrigeration and should not be assumed to share the storage properties of incobotulinumtoxinA formulations.

Shipping conditions carry real weight in this product class, because temperature excursions during transit can compromise potency without producing any visible change to the vial. Practitioners should inspect cold-chain documentation on arrival, confirm expiry dates and lot numbers before accepting delivery, and handle all BTX-A products strictly per the applicable IFU.
Legal Status and FDA Approval
Botulinum toxin products are prescription-only medicines in all markets. They are not available over the counter, and administration is restricted to licensed medical professionals with appropriate training in anatomy, dosing, administration technique, and complication management.

Several botulinum toxin products hold FDA approval in the United States, among them BOTOX®, DYSPORT®, XEOMIN®, and JEUVEAU®, though approval is granted per indication rather than to a brand as a whole. A product approved for glabellar lines does not thereby hold approval for migraine, spasticity, or any other therapeutic use, and labels are updated as new indications are added or revised.

Other brands carry CE marking in European markets or hold approvals in specific international markets. Regulatory status varies by country and by indication, and approval in one market should never be assumed to carry into another. Doctor Medica’s staff work exclusively with verified, licensed practitioners.
Price of Botulinum Toxin — What Practitioners Should Know
The cost of botulinum toxin injections varies by brand, vial size, unit count, country of manufacture, and order volume. Korean brands typically sit at more competitive per-vial pricing, which has contributed materially to their growing adoption in international aesthetic practice.

Vial price is the wrong number to compare on. Because potency units are assay-specific and not equivalent between manufacturers, the cost of botulinum toxin injections depends more on the unit system than on what the vial itself costs, which makes cost per treatment area the useful figure. A product that looks expensive per vial can come out cheaper per treatment, and the reverse happens just as often, with the indication doing most of the work.

Licensed practitioners seeking information on current pricing can contact Doctor Medica’s staff for guidance on product documentation and more.
Side Effects and Safety Considerations
Common botulinum toxin side effects are localized and typically transient. They include injection-site bruising, tenderness, headache, and erythema. Indication-specific effects require practitioner awareness. Upper-face procedures carry risks of ptosis, brow asymmetry, and dry eye, while treatment of neck or throat-related indications raises the possibility of dysphagia. Therapeutic applications involving larger muscles or higher cumulative doses warrant thorough risk assessment before each treatment.

Rare but serious adverse events include spread of toxin effect beyond the injection site. FDA labeling for botulinum toxin products carries a boxed warning describing potential distant-spread symptoms, among them swallowing difficulties, breathing changes, generalized weakness, and speech changes. [5]

Established contraindications include hypersensitivity to the toxin or its excipients, human albumin included, active infection at the proposed injection site, pregnancy and breastfeeding, and neuromuscular junction disorders such as myasthenia gravis or Lambert-Eaton syndrome.
How to Buy Botulinum Toxin Online at Wholesale Prices
Because botulinum toxin sits in a prescription pharmaceutical category, sourcing carries compliance obligations that do not attach to devices or cosmetics. Practitioners who buy botulinum toxin wholesale should confirm cold-chain compliance, LOT number traceability, and distributor credentials before accepting delivery, and requirements to purchase botulinum toxin online differ enough by jurisdiction that regional regulations warrant checking before proceeding.

Doctor Medica has worked alongside licensed aesthetic and medical professionals for over fifteen years, and our staff can provide clinical and documentation support to practitioners evaluating their options. Licensed professionals looking to order botulinum toxin injections for a new indication or buy BTX products across multiple brands can contact Doctor Medica’s staff for guidance on availability, documentation, and LOT traceability requirements. Practitioners who order botulinum toxin at wholesale volumes, or who buy BTX for the first time, should request full product documentation before finalizing any arrangement.

Clinics preparing to purchase botulinum toxin for professional use generally weigh distributor credentials and storage handling ahead of headline price. Those who want to buy botulinum toxin injections at wholesale volumes, or purchase botulinum toxin online for the first time, can request the same documentation guidance covering the full category.
FAQs
What is botulinum toxin?
It is a neurotoxic protein produced by Clostridium botulinum. In medical and aesthetic use, purified botulinum toxin type A is injected in controlled doses to temporarily block neuromuscular transmission, producing localized muscle relaxation in targeted areas. [1]
Is botulinum toxin the same as BOTOX®?
No. Botulinum toxin is the active drug category, while BOTOX® is one brand of botulinum toxin type A manufactured by AbbVie, analogous to the distinction between a generic drug name and a trade name. Other BTX-A brands include DYSPORT®, XEOMIN®, JEUVEAU®, NABOTA®, BOTULAX®, and INNOTOX®, depending on the market.
What are the types of botulinum toxin?
Serotypes run A through G, and type A is the standard for aesthetic and most therapeutic injections. Type B, rimabotulinumtoxinB marketed as MYOBLOC®, is used in selected neurological indications. Commercial BTX-A products comprise onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, and prabotulinumtoxinA.
What conditions can botulinum toxin treat?
Aesthetic uses include glabellar lines, crow’s feet, forehead lines, brow positioning, lip flip, neck bands, jaw slimming, and hyperhidrosis. Therapeutic uses include chronic migraine, blepharospasm, cervical dystonia, overactive bladder, and spasticity management, including rehabilitation applications. Approved indications vary by brand and jurisdiction.
How long does Botox last compared with other BTX-A products?
Commonly reported duration is 3 to 4 months for most aesthetic indications, with early effects visible at 3 to 7 days and full results assessed at 10 to 14 days. Some therapeutic indications sustain effect up to 6 months, with duration influenced by dose, muscle mass, metabolism, product, and treatment area.
What are the side effects of botulinum toxin?
Common effects include bruising, swelling, headache, and transient injection-site discomfort. Indication-specific risks include eyelid ptosis and asymmetry in upper-face work and dysphagia in certain neck and throat indications. In contrast, rare serious risks include spread of toxin effect beyond the injection site, described in the FDA boxed warning. [5]
What is the difference between Korean and Western botulinum toxin brands?
Western brands such as BOTOX®, DYSPORT®, and XEOMIN® hold long regulatory histories and broad FDA and EMA recognition. Korean brands including NABOTA®, BOTULAX®, INNOTOX®, and MEDITOXIN® are manufactured in South Korea under modern pharmaceutical standards and have gained international adoption through competitive pricing, a growing evidence base, and expanding approvals.
How can licensed professionals buy botulinum toxin online?
Licensed practitioners can contact Doctor Medica’s staff to receive information and guidance on documentation and availability. Authenticity, lot traceability, cold-chain compliance, and local regulatory requirements should all be verified before any procurement decision is finalized.

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.

Citations

[1] Hexsel C, Hexsel D, Porto MD, Schilling J, Siega C. Botulinum toxin type A for aging face and aesthetic uses. Dermatol Ther. 2011;24(1):54-61. doi:10.1111/j.1529-8019.2010.01378.x

[2] Sundaram H, Signorini M, Liew S, et al. Global Aesthetics Consensus: Botulinum Toxin Type A–Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications. Plast Reconstr Surg. 2016;137(3):518e-529e. doi:10.1097/01.prs.0000475758.63709.23

[3] Albrecht P, Jansen A, Lee JI, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 2019;92(1):e48-e54. https://pubmed.ncbi.nlm.nih.gov/30464031/

[4] Kaufman-Janette J, Cox SE, Dayan S, Joseph J. Botulinum Toxin Type A for Glabellar Frown Lines: What Impact of Higher Doses on Outcomes?. Toxins (Basel). 2021;13(7):494. Published 2021 Jul 16. doi:10.3390/toxins13070494

[5] U.S. Food and Drug Administration. JEUVEAU (prabotulinumtoxinA-xvfs) for injection, for intramuscular use. Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761085s000lbl.pdf

Written by Doctor Medica’s Editorial team

The content on this page has been written and fact-checked in accordance with our Editorial Policy. Clinical claims are sourced from peer-reviewed literature, regulatory documentation, and manufacturer specifications. Where citations are provided, it is always in accordance to our editorial standards.